Skip to main content
AAN.com

Abstract

Objective: To investigate possible correlations between tumor location and genetic alterations in a series of oligodendrogliomas.
Methods: A series of 158 consecutive oligodendrogliomas were retrospectively reviewed. In each case, the radiologic picture and the chromosome 1p (chr 1p) status of the tumor detected by the loss of heterozygosity technique were analyzed. Correlation between tumor location and molecular profile was made by χ2 tests.
Results: Eighty-eight of the 158 patients had low-grade oligodendrogliomas, and 70 had anaplastic oligodendrogliomas. Overall, oligodendrogliomas with chr 1p loss were located preferentially in the anterior part of the brain, whereas tumors with intact chr 1p affected mainly the posterior part of the brain (p = 0.0038). In terms of lobar involvement, a preferential location of oligodendrogliomas with chr 1p loss was found in the frontal lobes as compared with the temporal, parietal, and occipital tumors (p < 0.01).
Conclusion: There is a significant correlation between loss of heterozygosity on chromosome 1p and tumor location in oligodendrogliomas, suggesting that subtypes of oligodendrogliomas could derive from site-specific precursors.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Fortin D, Cairncross JG, Hammond RR. Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery. 1999; 45: 1279–1291.
2.
Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997; 79: 1381–1393.
3.
Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001; 7: 839–845.
4.
Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. JNCI. 1998; 90: 1473–1479.
5.
Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low grade oligodendrogliomas or oligo-astrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004; 22: 3133–3138.
6.
Zlatescu MC, TheraniYazdi A, Sasaki H, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 2001; 61: 6713–6715.
7.
Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol. 2002; 161: 313–319.
8.
Möller TB, Reif E. Pocket atlas of sectional anatomy, computed tomography and magnetic resonance imaging, vol. 1: head, neck, spine and joints. 2nd ed. Stuttgart: Thieme Medical, 1994.
9.
Hoang-Xuan K, He J, Huguet S, et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology. 2001; 57: 1278–1281.
10.
Sasaki H, Zlatescu MC, Betensky RA, et al. Histopathological–molecular genetic correlations in referral pathologist–diagnosed low-grade “oligodendroglioma.” J Neuropathol Exp Neurol. 2002; 61: 58–63.
11.
Lleonart ME, Garcia-Foncillas J, Sanchez-Prieto R, et al. Microsatellite instability and p53 mutations in sporadic right and left colon carcinoma: different clinical and molecular implications. Cancer. 1998; 83: 889–895.
12.
Spassky N, Goujet-Zalc C, Parmantier E, et al. Multiple restricted origin of oligodendrocytes. J Neurosci. 1998; 18: 8331–8343.
13.
Spassky N, Heydon K, Mangatal A, et al. Sonic hedgehog-dependent emergence of oligodendrocytes in the telencephalon: evidence for a source of oligodendrocytes in the olfactory bulb that is independent of PDGFRα signaling. Development. 2001; 128: 4993–5004.
14.
Thomas JL, Spassky N, Perez Villegas EM, et al. Spatiotemporal development of oligodendrocytes in the embryonic brain. J Neurosci Res. 2000; 59: 471–476.
15.
Honnorat J, Aguera M, Zalc B, et al. POP66, a paraneoplastic encephalomyelitis-related antigen, is a marker of adult oligodendrocytes. J Neuropathol Exp Neurol. 1998; 57: 311–322.

Information & Authors

Information

Published In

Neurology®
Volume 63Number 12December 28, 2004
Pages: 2360-2362
PubMed: 15623700

Publication History

Received: June 17, 2004
Accepted: September 3, 2004
Published online: December 28, 2004
Published in print: December 28, 2004

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

F. Laigle-Donadey, MD
From the Fédération de Neurologie Mazarin (Drs. Laigle-Donadey, Lejeune, Carpentier, Sanson, Hoang-Xuan, and Delattre), Service de Neuroradiologie (Dr. Martin-Duverneuil), Service de Neurochirurgie (Drs. Capelle, Duffau, and Cornu), and Laboratoire de Neuropathologie (Drs. Kujas and Mokhtari), Groupe Hospitalier Pitié-Salpêtrière, and INSERM U 495 (Drs. Kujas, Mokhtari, Carpentier, Sanson, Hoang-Xuan, Thillet, and Delattre, E. Crinière), Paris, and INSERM U 472 (Dr. Broët), Hôpital Paul Brousse, Villejuif, France.
N. Martin-Duverneuil, MD
From the Fédération de Neurologie Mazarin (Drs. Laigle-Donadey, Lejeune, Carpentier, Sanson, Hoang-Xuan, and Delattre), Service de Neuroradiologie (Dr. Martin-Duverneuil), Service de Neurochirurgie (Drs. Capelle, Duffau, and Cornu), and Laboratoire de Neuropathologie (Drs. Kujas and Mokhtari), Groupe Hospitalier Pitié-Salpêtrière, and INSERM U 495 (Drs. Kujas, Mokhtari, Carpentier, Sanson, Hoang-Xuan, Thillet, and Delattre, E. Crinière), Paris, and INSERM U 472 (Dr. Broët), Hôpital Paul Brousse, Villejuif, France.
J. Lejeune, PhD
From the Fédération de Neurologie Mazarin (Drs. Laigle-Donadey, Lejeune, Carpentier, Sanson, Hoang-Xuan, and Delattre), Service de Neuroradiologie (Dr. Martin-Duverneuil), Service de Neurochirurgie (Drs. Capelle, Duffau, and Cornu), and Laboratoire de Neuropathologie (Drs. Kujas and Mokhtari), Groupe Hospitalier Pitié-Salpêtrière, and INSERM U 495 (Drs. Kujas, Mokhtari, Carpentier, Sanson, Hoang-Xuan, Thillet, and Delattre, E. Crinière), Paris, and INSERM U 472 (Dr. Broët), Hôpital Paul Brousse, Villejuif, France.
E. Crinière, MSc
From the Fédération de Neurologie Mazarin (Drs. Laigle-Donadey, Lejeune, Carpentier, Sanson, Hoang-Xuan, and Delattre), Service de Neuroradiologie (Dr. Martin-Duverneuil), Service de Neurochirurgie (Drs. Capelle, Duffau, and Cornu), and Laboratoire de Neuropathologie (Drs. Kujas and Mokhtari), Groupe Hospitalier Pitié-Salpêtrière, and INSERM U 495 (Drs. Kujas, Mokhtari, Carpentier, Sanson, Hoang-Xuan, Thillet, and Delattre, E. Crinière), Paris, and INSERM U 472 (Dr. Broët), Hôpital Paul Brousse, Villejuif, France.
L. Capelle, MD
From the Fédération de Neurologie Mazarin (Drs. Laigle-Donadey, Lejeune, Carpentier, Sanson, Hoang-Xuan, and Delattre), Service de Neuroradiologie (Dr. Martin-Duverneuil), Service de Neurochirurgie (Drs. Capelle, Duffau, and Cornu), and Laboratoire de Neuropathologie (Drs. Kujas and Mokhtari), Groupe Hospitalier Pitié-Salpêtrière, and INSERM U 495 (Drs. Kujas, Mokhtari, Carpentier, Sanson, Hoang-Xuan, Thillet, and Delattre, E. Crinière), Paris, and INSERM U 472 (Dr. Broët), Hôpital Paul Brousse, Villejuif, France.
H. Duffau, MD
From the Fédération de Neurologie Mazarin (Drs. Laigle-Donadey, Lejeune, Carpentier, Sanson, Hoang-Xuan, and Delattre), Service de Neuroradiologie (Dr. Martin-Duverneuil), Service de Neurochirurgie (Drs. Capelle, Duffau, and Cornu), and Laboratoire de Neuropathologie (Drs. Kujas and Mokhtari), Groupe Hospitalier Pitié-Salpêtrière, and INSERM U 495 (Drs. Kujas, Mokhtari, Carpentier, Sanson, Hoang-Xuan, Thillet, and Delattre, E. Crinière), Paris, and INSERM U 472 (Dr. Broët), Hôpital Paul Brousse, Villejuif, France.
P. Cornu, MD
From the Fédération de Neurologie Mazarin (Drs. Laigle-Donadey, Lejeune, Carpentier, Sanson, Hoang-Xuan, and Delattre), Service de Neuroradiologie (Dr. Martin-Duverneuil), Service de Neurochirurgie (Drs. Capelle, Duffau, and Cornu), and Laboratoire de Neuropathologie (Drs. Kujas and Mokhtari), Groupe Hospitalier Pitié-Salpêtrière, and INSERM U 495 (Drs. Kujas, Mokhtari, Carpentier, Sanson, Hoang-Xuan, Thillet, and Delattre, E. Crinière), Paris, and INSERM U 472 (Dr. Broët), Hôpital Paul Brousse, Villejuif, France.
P. Broët, MD, PhD
From the Fédération de Neurologie Mazarin (Drs. Laigle-Donadey, Lejeune, Carpentier, Sanson, Hoang-Xuan, and Delattre), Service de Neuroradiologie (Dr. Martin-Duverneuil), Service de Neurochirurgie (Drs. Capelle, Duffau, and Cornu), and Laboratoire de Neuropathologie (Drs. Kujas and Mokhtari), Groupe Hospitalier Pitié-Salpêtrière, and INSERM U 495 (Drs. Kujas, Mokhtari, Carpentier, Sanson, Hoang-Xuan, Thillet, and Delattre, E. Crinière), Paris, and INSERM U 472 (Dr. Broët), Hôpital Paul Brousse, Villejuif, France.
M. Kujas, MD
From the Fédération de Neurologie Mazarin (Drs. Laigle-Donadey, Lejeune, Carpentier, Sanson, Hoang-Xuan, and Delattre), Service de Neuroradiologie (Dr. Martin-Duverneuil), Service de Neurochirurgie (Drs. Capelle, Duffau, and Cornu), and Laboratoire de Neuropathologie (Drs. Kujas and Mokhtari), Groupe Hospitalier Pitié-Salpêtrière, and INSERM U 495 (Drs. Kujas, Mokhtari, Carpentier, Sanson, Hoang-Xuan, Thillet, and Delattre, E. Crinière), Paris, and INSERM U 472 (Dr. Broët), Hôpital Paul Brousse, Villejuif, France.
K. Mokhtari, MD
From the Fédération de Neurologie Mazarin (Drs. Laigle-Donadey, Lejeune, Carpentier, Sanson, Hoang-Xuan, and Delattre), Service de Neuroradiologie (Dr. Martin-Duverneuil), Service de Neurochirurgie (Drs. Capelle, Duffau, and Cornu), and Laboratoire de Neuropathologie (Drs. Kujas and Mokhtari), Groupe Hospitalier Pitié-Salpêtrière, and INSERM U 495 (Drs. Kujas, Mokhtari, Carpentier, Sanson, Hoang-Xuan, Thillet, and Delattre, E. Crinière), Paris, and INSERM U 472 (Dr. Broët), Hôpital Paul Brousse, Villejuif, France.
A. Carpentier, MD
From the Fédération de Neurologie Mazarin (Drs. Laigle-Donadey, Lejeune, Carpentier, Sanson, Hoang-Xuan, and Delattre), Service de Neuroradiologie (Dr. Martin-Duverneuil), Service de Neurochirurgie (Drs. Capelle, Duffau, and Cornu), and Laboratoire de Neuropathologie (Drs. Kujas and Mokhtari), Groupe Hospitalier Pitié-Salpêtrière, and INSERM U 495 (Drs. Kujas, Mokhtari, Carpentier, Sanson, Hoang-Xuan, Thillet, and Delattre, E. Crinière), Paris, and INSERM U 472 (Dr. Broët), Hôpital Paul Brousse, Villejuif, France.
M. Sanson, MD, PhD
From the Fédération de Neurologie Mazarin (Drs. Laigle-Donadey, Lejeune, Carpentier, Sanson, Hoang-Xuan, and Delattre), Service de Neuroradiologie (Dr. Martin-Duverneuil), Service de Neurochirurgie (Drs. Capelle, Duffau, and Cornu), and Laboratoire de Neuropathologie (Drs. Kujas and Mokhtari), Groupe Hospitalier Pitié-Salpêtrière, and INSERM U 495 (Drs. Kujas, Mokhtari, Carpentier, Sanson, Hoang-Xuan, Thillet, and Delattre, E. Crinière), Paris, and INSERM U 472 (Dr. Broët), Hôpital Paul Brousse, Villejuif, France.
K. Hoang-Xuan, MD, PhD
From the Fédération de Neurologie Mazarin (Drs. Laigle-Donadey, Lejeune, Carpentier, Sanson, Hoang-Xuan, and Delattre), Service de Neuroradiologie (Dr. Martin-Duverneuil), Service de Neurochirurgie (Drs. Capelle, Duffau, and Cornu), and Laboratoire de Neuropathologie (Drs. Kujas and Mokhtari), Groupe Hospitalier Pitié-Salpêtrière, and INSERM U 495 (Drs. Kujas, Mokhtari, Carpentier, Sanson, Hoang-Xuan, Thillet, and Delattre, E. Crinière), Paris, and INSERM U 472 (Dr. Broët), Hôpital Paul Brousse, Villejuif, France.
J. Thillet, PhD
From the Fédération de Neurologie Mazarin (Drs. Laigle-Donadey, Lejeune, Carpentier, Sanson, Hoang-Xuan, and Delattre), Service de Neuroradiologie (Dr. Martin-Duverneuil), Service de Neurochirurgie (Drs. Capelle, Duffau, and Cornu), and Laboratoire de Neuropathologie (Drs. Kujas and Mokhtari), Groupe Hospitalier Pitié-Salpêtrière, and INSERM U 495 (Drs. Kujas, Mokhtari, Carpentier, Sanson, Hoang-Xuan, Thillet, and Delattre, E. Crinière), Paris, and INSERM U 472 (Dr. Broët), Hôpital Paul Brousse, Villejuif, France.
J. Y. Delattre, MD
From the Fédération de Neurologie Mazarin (Drs. Laigle-Donadey, Lejeune, Carpentier, Sanson, Hoang-Xuan, and Delattre), Service de Neuroradiologie (Dr. Martin-Duverneuil), Service de Neurochirurgie (Drs. Capelle, Duffau, and Cornu), and Laboratoire de Neuropathologie (Drs. Kujas and Mokhtari), Groupe Hospitalier Pitié-Salpêtrière, and INSERM U 495 (Drs. Kujas, Mokhtari, Carpentier, Sanson, Hoang-Xuan, Thillet, and Delattre, E. Crinière), Paris, and INSERM U 472 (Dr. Broët), Hôpital Paul Brousse, Villejuif, France.

Notes

Address correspondence and reprint requests to Dr. J.-Y. Delattre, Fédération de Neurologie Mazarin, Groupe Hospitalier Pitié-Salpêtrière, 47 boulevard de l’hôpital, 75651 Paris Cedex 13, France; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. "Describing some general aspects on the anatomoneuropathology, neuropsychological assessment and some genetics of Glioblastoma Multiforme", Annals of the Academy of Romanian Scientists Series on Biological Sciences, 12, 1, (95-107), (2023).https://doi.org/10.56082/annalsarscibio.2023.1.95
    Crossref
  2. White Matter Tracts and Diffuse Lower-Grade Gliomas: The Pivotal Role of Myelin Plasticity in the Tumor Pathogenesis, Infiltration Patterns, Functional Consequences and Therapeutic Management, Frontiers in Oncology, 12, (2022).https://doi.org/10.3389/fonc.2022.855587
    Crossref
  3. Can Tumor Location on Pre-treatment MRI Predict Likelihood of Pseudo-Progression vs. Tumor Recurrence in Glioblastoma?—A Feasibility Study, Frontiers in Computational Neuroscience, 14, (2020).https://doi.org/10.3389/fncom.2020.563439
    Crossref
  4. Gaps and Doubts in Search to Recognize Glioblastoma Cellular Origin and Tumor Initiating Cells, Journal of Oncology, 2020, (1-15), (2020).https://doi.org/10.1155/2020/6783627
    Crossref
  5. “Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas, Neuro-Oncology, 22, 7, (936-943), (2020).https://doi.org/10.1093/neuonc/noaa041
    Crossref
  6. Is the anatomical distribution of low-grade gliomas linked to regions of gliogenesis?, Journal of Neuro-Oncology, 147, 1, (147-157), (2020).https://doi.org/10.1007/s11060-020-03409-8
    Crossref
  7. Differences in the preferential location and invasiveness of diffuse low‐grade gliomas and their impact on outcome, Cancer Medicine, 9, 15, (5446-5458), (2020).https://doi.org/10.1002/cam4.3216
    Crossref
  8. Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups, Neuro-Oncology Advances, 1, 1, (2019).https://doi.org/10.1093/noajnl/vdz001
    Crossref
  9. BRAIN AND SPINAL CORD TUMORS, Cancer, (395-414), (2019).https://doi.org/10.1002/9781119645214.ch22
    Crossref
  10. Prognostic Significance of Anatomic Origin and Evaluation of Survival Statistics of Astrocytoma Patients—a Tertiary Experience, Indian Journal of Surgical Oncology, 10, 1, (55-60), (2018).https://doi.org/10.1007/s13193-018-0820-0
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share